Rubius Therapeutics (NASDAQ:RUBY) and Vigil Neuroscience (NASDAQ:VIGL) Critical Survey
Rubius Therapeutics (NASDAQ:RUBY) and Vigil Neuroscience (NASDAQ:VIGL) Critical Survey
Rubius Therapeutics (NASDAQ:RUBY – Get Rating) and Vigil Neuroscience (NASDAQ:VIGL – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.
Rubius Therapeutics（納斯達克股票代碼：RUBY — 獲取評級）和Vigil Neuroscience（納斯達克股票代碼：VIGL — 獲取評級）都是小型醫療公司，但哪家更勝一籌？我們將根據兩家企業的盈利能力、分析師建議、股息、風險、收益、估值和機構所有權進行比較。
Analyst Ratings
分析師評級
This is a breakdown of recent ratings and target prices for Rubius Therapeutics and Vigil Neuroscience, as provided by MarketBeat.com.
這是Marketbeat.com提供的Rubius Therapeutics和Vigil Neuroscience最近的評級和目標價格的明細。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rubius Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
| Vigil Neuroscience | 0 | 1 | 4 | 0 | 2.80 |
| 賣出評級 | 持有評級 | 買入評級 | 強勁的買入評級 | 評分分數 | |
| 魯比烏斯療法 | 0 | 1 | 0 | 0 | 2.00 |
| 守夜神經科學 | 0 | 1 | 4 | 0 | 2.80 |
Rubius Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 37,995.24%. Vigil Neuroscience has a consensus target price of $18.80, suggesting a potential upside of 88.19%. Given Rubius Therapeutics' higher probable upside, equities research analysts clearly believe Rubius Therapeutics is more favorable than Vigil Neuroscience.
Rubius Therapeutics目前的共識目標價格爲8.00美元，這表明潛在的上漲空間爲37,995.24％。Vigil Neuroscience的共識目標價爲18.80美元，表明潛在的上漲空間爲88.19％。鑑於Rubius Therapeutics可能有更高的上漲空間，股票研究分析師顯然認爲Rubius Therapeutics比Vigil Neuroceut
Risk and Volatility
風險和波動性
Rubius Therapeutics has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 3.43, meaning that its stock price is 243% more volatile than the S&P 500.
Rubius Therapeutics的beta值爲2.38，這意味着其股價的波動性比標準普爾500指數高138％。相比之下，Vigil Neuroscience的beta值爲3.43，這意味着其股價的波動性比標準普爾500指數高243％。
Earnings & Valuation
收益與估值
This table compares Rubius Therapeutics and Vigil Neuroscience's revenue, earnings per share and valuation.
該表比較了Rubius Therapeutics和Vigil Neursociale的收入、每股收益和估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rubius Therapeutics | N/A | N/A | -$179.67 million | ($2.38) | -0.01 |
| Vigil Neuroscience | N/A | N/A | -$68.31 million | ($2.19) | -4.56 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股收益 | 市盈率 | |
| 魯比烏斯療法 | 不適用 | 不適用 | -1.7967 億美元 | (2.38 美元) | -0.01 |
| 守夜神經科學 | 不適用 | 不適用 | -6,831 萬美元 | (2.19 美元) | -4.56 |
Vigil Neuroscience is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.
Vigil Neuroscies的市盈率低於Rubius Therapeutics，這表明它目前是這兩隻股票中更實惠的一隻。
Insider & Institutional Ownership
內幕和機構所有權
76.1% of Rubius Therapeutics shares are held by institutional investors. Comparatively, 88.9% of Vigil Neuroscience shares are held by institutional investors. 5.3% of Rubius Therapeutics shares are held by company insiders. Comparatively, 46.6% of Vigil Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
76.1％的Rubius Therapeutics股票由機構投資者持有。相比之下，88.9％的Vigil Neuroscience股票由機構投資者持有。5.3％的Rubius Therapeutics股票由公司內部人士持有。相比之下，Vigil Neursical 46.6％的股票由公司內部人士持有。強大的機構所有權表明大型基金經理、對沖基金和捐贈機構認爲，從長遠來看，一家公司的表現將優於市場。
Profitability
盈利能力
This table compares Rubius Therapeutics and Vigil Neuroscience's net margins, return on equity and return on assets.
該表比較了Rubius Therapeutics和Vigil Neuroscies的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Rubius Therapeutics | N/A | -212.29% | -86.74% |
| Vigil Neuroscience | N/A | -38.38% | -36.59% |
| 淨利潤 | 股本回報率 | 資產回報率 | |
| 魯比烏斯療法 | 不適用 | -212.29% | -86.74% |
| 守夜神經科學 | 不適用 | -38.38% | -36.59% |
Summary
摘要
Vigil Neuroscience beats Rubius Therapeutics on 9 of the 11 factors compared between the two stocks.
在比較兩隻股票的11個因素中，Vigil Neuroscies在9個因素上擊敗了Rubius Therape
About Rubius Therapeutics
關於魯比烏斯療法
(Get Rating)
（獲取評級）
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA.
Rubius Therapeutics, Inc. 從事紅細胞治療藥物的開發。它爲癌症、自身免疫性疾病、血友病、傳染病和代謝性疾病提供藥物。該公司成立於2013年4月26日，總部位於馬薩諸塞州福克斯伯勒。
About Vigil Neuroscience
關於 Vigil 神經科學
(Get Rating)
（獲取評級）
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.
Vigil Neuroscionce, Inc. 是一家專注於小膠質細胞的公司，致力於爲患有罕見和常見神經退行性疾病的患者、護理人員和家庭開發改善疾病的療法。其主要候選產品是 VGL101，這是一種全人源單克隆抗體 (mAb)，旨在激活骨髓細胞 2 (TREM2) 上表達的觸發受體，該受體處於 I 期，用於治療成人發作的軸突球體和色素膠質細胞白質腦病，也用於治療腦腎上腺白質營養不良和阿爾茨海默病。該公司還開發了一種適用於口服給藥的小分子 TREM2 激動劑，用於治療與小膠質細胞功能障礙相關的常見神經退行性疾病。Vigil Neuroscionce, Inc. 成立於 2020 年，總部位於馬薩諸塞州劍橋。Vigil Neuroscience, Inc. 作爲安進公司的子公司運營。
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Rubius Therapeutics 每日新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Rubius Therapeutics及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。